Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

December 24, 2024

Conditions
Advanced Breast Cancer
Interventions
DRUG

Palbociclib

125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle

DRUG

Letrozole

2.5 mg , orally once daily (continuously)

Trial Locations (7)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital/Oncology department, Beijing

130021

The first hospital of jilin university, Changchun

150081

Harbin Medical University Cancer Hospital, Harbin

310003

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

510060

Sun Yat-Sen University Cancer Center, Guangzhou

510080

Guangdong General Hospital/Department of Breast Surgery, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02499146 - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer | Biotech Hunter | Biotech Hunter